Novartis AG
Company Snapshot
Founded: 1996
Entity Type: Public
Employees: 76057
Region: U.S. and Europe
Revenue: $45,440 Millions
Revenue Year: 2023
Segment: Oncology
Headquarter: Basel, Switzerland
Corporate Address: Lichtstrasse 35 CH-4056 Basel, Switzerland Tel: +41-61-324-1111 Web: www.novartis.com
Company Overview
Novartis AG, founded in 1996, is a multinational conglomerate specializing in exploring, advancing, producing and promoting a diverse range of pharmaceuticals and cost-effective generic medicines. Novartis AG operates through its Innovative Medicines and Sandoz divisions, with a workforce of 76,057 employees globally as of December 2023.
The Innovative Medicines division encompasses two global business units: Novartis Oncology and Novartis Pharmaceuticals. Its primary focus is in core therapeutic areas such as cardiovascular, immunology, neuroscience, solid tumors and hematology.
Financial Highlights (FY 2023)
Net Revenue: ***
Total Current Liabilities: ***
Total Current Assets: ***
R&D expenses: ***
Operating Income: ***
This information is available for BCC Research members only.
Company's Business Segments
- Cardiovascular, renal and metabolic : Entresto, Leqvio, and Other
- Immunology : Cosentyx, Xolai, Ilaris, and Other
- Neuroscience : Kesimpta, Zolgensma, Mayzent, Aimovig, and Other
- Oncology : Promacta/Revolade, Kisqali, Tafinlar + Mekinist, Tasigna, Jakavi, Pluvicto, Lutathera, Kymriah, Piqray/Vijoice, Scemblix, Votrient, Adakveo, Tabrecta, and other
- Established brands : Lucentis, Sandostatin, Gilenya, Exforge Group, Galvus Group, Diovan Group, Gleevec/Glivec, Afinitor/Votubia, Contract manufacturing, and Other
Applications/End User Industries
- Cardiovascular
- Immunology
- Neuroscience
- Oncology
- Metabolic
- Renal
BCC Research Beacon 